公开(公告)号：US12049480B2

公开(公告)日：2024-07-30

申请号：US18518304

申请日：2023-11-22

申请人： Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Centre National de la Recherche Scientifique (CNRS) ,  Ecole Normale Superieure de Lyon ,  Universite Claude Bernard Lyon 1

发明人： Théophile Ohlmann ,  Philippe Mangeot ,  Emiliano Ricci

IPC分类号： C07K14/005 ,  C12N7/00 ,  C12N9/22 ,  C12N15/10 ,  C12N15/113

CPC分类号： C07K14/005 ,  C12N7/00 ,  C12N9/22 ,  C12N15/102 ,  C12N15/113 ,  C07K2319/00 ,  C07K2319/43 ,  C07K2319/50 ,  C12N2310/20 ,  C12N2740/10023 ,  C12N2740/10042 ,  C12N2740/13023 ,  C12N2740/13042 ,  C12N2800/80

摘要： The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.

公开(公告)号：US20240109940A1

公开(公告)日：2024-04-04

申请号：US18518304

申请日：2023-11-22

申请人： Institut National De La Sante Et De La Recherche Medicale (INSERM) ,  Centre National De La Recherche Scientifique (CNRS) ,  Ecole Normale Superieure De Lyon ,  Universite Claude Bernard Lyon 1

发明人： Théophile OHLMANN ,  Philippe MANGEOT ,  Emiliano RICCI

IPC分类号： C07K14/005 ,  C12N7/00 ,  C12N9/22 ,  C12N15/10 ,  C12N15/113

CPC分类号： C07K14/005 ,  C12N7/00 ,  C12N9/22 ,  C12N15/102 ,  C12N15/113 ,  C07K2319/00 ,  C07K2319/43 ,  C07K2319/50 ,  C12N2310/20 ,  C12N2740/10023 ,  C12N2740/10042 ,  C12N2740/13023 ,  C12N2740/13042 ,  C12N2800/80

摘要： The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.

公开(公告)号：US20180016558A1

公开(公告)日：2018-01-18

申请号：US15547094

申请日：2016-01-29

申请人： MockV Solutions, Inc.

发明人： David Cetlin ,  Arun Dhar

IPC分类号： C12N7/00 ,  G01N33/569 ,  C12Q1/70

CPC分类号： C12N7/00 ,  C12N2740/10023 ,  C12N2740/10051 ,  C12N2740/13051 ,  C12Q1/702 ,  G01N33/56983 ,  G01N2333/15

摘要： The present invention relates to a stock solution (RLP Stock Solution) of mammalian cell-endogenous retrovirus like particles (RLP, a method of preparing a RLP stock solution, a kit containing a RLP stock solution, and a method of quantifying the amount of RLP removed from a solution. An RLP stock solution will contain a high concentration of RLP and an extremely low amount of any therapeutic proteins of interest. In some instances, an RLP stock solution will contain a very low amount of natural mammalian host cell protein (HCP) and DNA. The method of preparing a RLP stock solution will consist of the production of RLP during fermentation or cell culturing and the subsequent purification of RLP from fermentation or cell culture solution. The kit will comprise at least two containers. One container comprised of RLP stock solution and one comprised of PCR primers or one or more antibodies. The method of quantifying RLP comprises the steps of adding RLP stock solution to an in-process solution containing a recombinant therapeutic of interest, processing the resulting solution through a bioprocess purification technique, and then quantifying the amount of RLP removed.

公开(公告)号：US12023377B2

公开(公告)日：2024-07-02

申请号：US17732076

申请日：2022-04-28

申请人： INPROTHER APS

发明人： Peter Holst ,  Christian Thirion ,  Lasse Neukirch

IPC分类号： A61K39/00 ,  A61K39/21 ,  A61K39/235 ,  A61P35/00 ,  A61P35/04 ,  A61P37/04 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86

CPC分类号： A61K39/235 ,  A61K39/21 ,  A61P35/00 ,  A61P35/04 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  A61K2039/525 ,  A61K2039/5258 ,  A61K2039/545 ,  A61K2039/585 ,  C12N2710/10043 ,  C12N2740/10022 ,  C12N2740/10023 ,  C12N2740/10034 ,  C12N2740/10071

摘要： The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.

公开(公告)号：US20240018544A1

公开(公告)日：2024-01-18

申请号：US18351800

申请日：2023-07-13

申请人： The General Hospital Corporation ,  President and Fellows of Harvard College

发明人： J. Keith Joung ,  Peter Cabeceiras

IPC分类号： C12N15/86 ,  C07K14/005

CPC分类号： C12N15/86 ,  C07K14/005 ,  C12N2740/10023 ,  C12N2740/10042 ,  C12N2740/10052

摘要： Human-derived virus-like particles (heVLPs), comprising a membrane comprising a phospholipid bilayer with one or more HERV-derived envelope proteins on the external side; one or more HERV-derived GAG proteins in the heVLP core, and a cargo molecule, e.g., a biomolecule and/or chemical cargo molecule, disposed in the core of the heVLP on the inside of the membrane, wherein the heVLP does not comprise a gag protein, except for gag proteins that are encoded in the human genome or gag proteins that are encoded by a consensus sequence that is derived from gag proteins found in the human genome, and methods of use thereof for delivery of the cargo molecule to cells.

公开(公告)号：US20170192001A1

公开(公告)日：2017-07-06

申请号：US15456487

申请日：2017-03-11

申请人： MockV Solutions, Inc.

发明人： David Cetlin ,  Arun Dhar

IPC分类号： G01N33/569 ,  C12Q1/70

CPC分类号： G01N33/56983 ,  A61K39/12 ,  A61K39/21 ,  A61K39/23 ,  A61K2039/5258 ,  C12N2740/10023 ,  C12N2750/14023 ,  C12Q1/701 ,  C12Q2600/158 ,  G01N2333/015 ,  G01N2333/15

摘要： The present invention relates to a method of quantifying the amount of Mock Virus Particles (MVP) removed from a solution as a result of processing that solution through a purification technique. This method involves the steps of adding MVP to a solution, processing the solution through a purification technique, quantifying the amount of MVP removed from the solution. The present invention also relates to a kit that can be used in conjunction with the method. This kit will comprise at least one stock solution of MVP and at least one quantification solution.

公开(公告)号：US20240228546A9

公开(公告)日：2024-07-11

申请号：US18130375

申请日：2023-04-03

申请人： Institut National De La Sante Et De La Recherche Medicale (INSERM) ,  Centre National De La Recherche Scientifique (CNRS) ,  Ecole Normale Superieure De Lyon ,  Universite Claude Bernard Lyon 1

发明人： Théophile OHLMANN ,  Philippe MANGEOT ,  Emiliano RICCI

IPC分类号： C07K14/005 ,  C12N7/00 ,  C12N9/22 ,  C12N15/10 ,  C12N15/113

CPC分类号： C07K14/005 ,  C12N7/00 ,  C12N9/22 ,  C12N15/102 ,  C12N15/113 ,  C07K2319/00 ,  C07K2319/43 ,  C07K2319/50 ,  C12N2310/20 ,  C12N2740/10023 ,  C12N2740/10042 ,  C12N2740/13023 ,  C12N2740/13042 ,  C12N2800/80

摘要： The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.

公开(公告)号：US20240200104A1

公开(公告)日：2024-06-20

申请号：US18282644

申请日：2022-03-18

申请人： Flagship Pioneering Innovations VI, LLC

发明人： Robert James Citorik ,  William Edward Salomon ,  Zi Jun Wang ,  Jacob Rosenblum Rubens ,  Benjamin Harris Weinberg

IPC分类号： C12N15/90 ,  C12N9/12 ,  C12N15/86

CPC分类号： C12N15/907 ,  C12N9/1276 ,  C12N15/86 ,  C12Y207/07049 ,  C12N2740/10022 ,  C12N2740/10023 ,  C12N2740/10043 ,  C12N2800/90

摘要： Methods and compositions for altering a genome at one or more locations in a host cell, tissue, or subject are disclosed.

公开(公告)号：US20240011050A1

公开(公告)日：2024-01-11

申请号：US18351689

申请日：2023-07-13

申请人： The General Hospital Corporation ,  President and Fellows of Harvard College

发明人： J. Keith Joung ,  Peter Cabeceiras

IPC分类号： C12N15/86 ,  C07K14/005

CPC分类号： C12N15/86 ,  C07K14/005 ,  C12N2740/10023 ,  C12N2740/10042 ,  C12N2740/10052

摘要： Human-derived virus-like particles (heVLPs), comprising a membrane comprising a phospholipid bilayer with one or more HERV-derived envelope proteins on the external side; one or more HERV-derived GAG proteins in the heVLP core, and a cargo molecule, e.g., a biomolecule and/or chemical cargo molecule, disposed in the core of the heVLP on the inside of the membrane, wherein the heVLP does not comprise a gag protein, except for gag proteins that are encoded in the human genome or gag proteins that are encoded by a consensus sequence that is derived from gag proteins found in the human genome, and methods of use thereof for delivery of the cargo molecule to cells.

公开(公告)号：US20180002767A1

公开(公告)日：2018-01-04

申请号：US15542265

申请日：2016-01-15

申请人： Takeda Vaccines, Inc.

发明人： Joel R. HAYNES ,  Evelyn BENSON

IPC分类号： C12Q1/70 ,  C12N7/00

CPC分类号： C12Q1/702 ,  C12N7/00 ,  C12N7/02 ,  C12N9/1276 ,  C12N2740/00011 ,  C12N2740/10023 ,  C12Q1/6806 ,  C12Q1/70 ,  C12Q1/701 ,  C12Y207/07049 ,  C12Y304/21062 ,  C12Q2521/107 ,  C12Q2527/137 ,  C12Q2563/149

摘要： The present invention relates to methods and kits for detecting in a sample the presence of a virus particle or a virus-like particle that has reverse transcriptase activity and methods for preparing a retroviral contaminant-free substance. An aspect of the present invention is a method for detecting the presence of a virus particle in a sample of a Virus-like Particle (VLP) drug substance comprising a step of performing PCR-based reverse transcriptase (PBRT) on a sample of the VLP drug substance that has been treated with a protease.